Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain

NCT ID: NCT02343003

Last Updated: 2019-05-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 151 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2017-03-16

Brief Summary

This study is designed to:

• Determine the effectiveness (primarily measured by pain relief) of Coolief when used to create radiofrequency lesions of the genicular nerves compared to pain relief following corticosteroid injection; and
• Confirm the safety of Coolief when used to perform radiofrequency lesions of the genicular nerves in subjects to manage knee pain compared to safety of corticosteroid injection

Detailed Description

This is a prospective, randomized, multicenter comparison study examining the outcomes of subjects having knee pain undergoing a procedure to create a radiofrequency lesion of the genicular nerves with the Coolief system compared to subjects receiving corticosteroid injection. A total of approximately 144 subjects will be enrolled into this study with subjects undergoing either radiofrequency neurotomy or corticosteroid injection in a 1:1 randomization scheme. Follow up will be conducted for a total of 12 months post Coolief procedure with the primary endpoint being completed at month 6. Subjects randomized to the comparison (corticosteroid) group will have the option to cross over to the neurotomy group after completing the 6 month endpoint assessment. They would then be followed for an additional 6 months. Pain, overall outcome, quality of life, pain medication use, and adverse events will be compared between the two treatment groups in order to determine success.

Primary Effectiveness Endpoint:

The proportion of subjects whose knee pain is reduced by ≥ 50% based on the NRS scale at 6 Months.

Primary Safety Endpoint:

The proportion of subjects experiencing adverse events through final follow up.

Secondary Effectiveness Endpoints:

• The proportion of subjects whose knee pain is reduced from baseline by ≥ 50% based on the Numeric Rating Scale (NRS) at 12 months.
• Improvement in global outcome from baseline as measured by the Oxford Knee Score at 6 months and 12 months.

Tertiary Effectiveness Endpoint:

Subject satisfaction as measured by the Global Perceived Effect Score at 6 months and 12 months.

Quaternary Effectiveness Endpoint:

Reduction in pain medication usage from baseline as measured by subject self-reported average daily dosage.

In addition, exploratory analyses of health economic indicators may be performed.

Subjects will participate in the study for up to 13 months (2 week roll-in period + treatment visit + 12 month follow up), except for subjects who participate in the optional crossover group. These crossover subjects will be on study for up to 15 months (2 week roll-in + treatment + 6 month follow-up and crossover + 6 month follow up). Enrollment is anticipated to take approximately 6-8 months.

Conditions

Osteoarthritis of the Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cooled radiofrequency

Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain

Group Type: EXPERIMENTAL

Cooled Radiofrequency

Intervention Type: DEVICE

Delivery of energy to ablate sensory nerves via cooled radiofrequency probe

Corticosteroid injection

Corticosteroid injections will be administered to study subjects' knees to reduce knee pain

Group Type: ACTIVE_COMPARATOR

Corticosteroid injection

Intervention Type: DRUG

Delivery of corticosteroid into knee by injection with needle to reduce knee pain

Interventions

Cooled Radiofrequency

Delivery of energy to ablate sensory nerves via cooled radiofrequency probe

Intervention Type: DEVICE

Corticosteroid injection

Delivery of corticosteroid into knee by injection with needle to reduce knee pain

Intervention Type: DRUG

Other Intervention Names

Coolief

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 21 years

2. Able to understand the informed consent form and provide written informed consent and able to complete outcome measures

3. History of chronic knee pain for longer than 6 months unresponsive to conservative treatments (PT, oral analgesics, intra-articular injections with steroids and/or viscosupplementation)

4. Positive response (defined as a decrease in numeric pain scores of at least 50%) to a geniculate nerve block of the index knee

5. Pain on NRS ≥ 6 on a 10 point scale for the index knee

6. Radiologic confirmation of osteoarthritis (x-ray/MRI/CT) of OA grade of 2 (mild), 3 (moderate) or 4 (severe) noted within 12 months for the index knee

7. Oxford Knee Score group at Baseline of ≤ 35 indicating moderate to severe OA in the index knee

8. If the patient is taking an opioid or other morphine equivalent medication, the dose must be considered clinically stable (defined as <10% change in dosage for ≥ 2 months prior to the screening visit).

9. Analgesics including membrane stabilizers such as Neurontin and antidepressants for pain such as Cymbalta must be clinically stable (defined as stable dosage for ≥ 6 weeks prior to the screening visit) and shall not change during the course of the study without approval of investigator. Agree to see one pain doctor (study investigator) for knee pain during the study period

10. Index knee pathology that is consistent with generally accepted indications for total knee arthroplasty.

11. Willing to delay any surgical intervention for the index knee for 12 months.

12. Willingness to provide informed consent and to comply with the requirements of this protocol for the full duration.

Exclusion Criteria

1. Pseudo arthritis, rheumatoid arthritis or other systemic inflammatory arthritis condition that could cause knee pain.

2. Previous or pending lower limb amputation.

3. Intra-articular steroid, platelet rich plasma (PRP) or hyaluronic acid injections in the index knee within 90 days from the screening visit.

4. An intra-articular corticosteroid injection is not indicated as an appropriate treatment option.

5. Prior radiofrequency of the genicular nerves of the index knee.

6. Prior partial, resurfacing, or total knee arthroplasty in index knee.

7. Clinically significant ligamentous laxity of the index knee.

8. Evidence of structural abnormality other than osteoarthritis of knee, hip or back that materially affects gait or function of the knee or is the underlying cause of the knee pain.

9. BMI > 40.

10. Extremely thin patients and those with minimal subcutaneous tissue thickness that would not accommodate a lesion of up to 14 mm in diameter to limit the risk of skin burns.

11. Pending or active compensation claim, litigation or disability remuneration (secondary gain) related to knee.

12. Pregnant or intent of becoming pregnant during the study period.

13. Chronic pain associated with significant psychosocial dysfunction.

14. Beck's Depression Index score of > 22 (indicates clinically depressed state).

15. Allergies to any of the medications to be used during the procedure.

16. Systemic or localized infection at needle entry sites (subject may be considered for inclusion once infection is resolved).

17. History of uncontrolled coagulopathy, ongoing coagulation treatment or unexplained or uncontrollable bleeding that is uncorrectable.

18. Identifiable anatomical variability that would materially alter the procedure as described in the protocol.

19. Within the preceding 2 years, subject has suffered from active narcotic addiction, substance or alcohol abuse.

20. Current prescribed opioid medications equivalent to greater than 60 morphine equivalent daily opioid dose.

21. Uncontrolled immunosuppression (e.g. AIDS, cancer, diabetes, etc.)

22. Subject currently implanted with pacemaker or defibrillator.

23. Participating in another clinical trial/investigation within 30 days prior to signing informed consent.

24. Subject unwilling or unable to comply with follow up schedule or protocol requirements.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Halyard Health

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David T Curd, MS

Role: STUDY_DIRECTOR

Halyard Health, Inc.

Locations

Valley Anesthesiology Consultants - Estrella

Phoenix, Arizona, United States

Valley Anesthesiology Consultants/Valley Pain Consultants

Scottsdale, Arizona, United States

Orthopedic Pain Specialists

Santa Monica, California, United States

Rush University Medical Center

Chicago, Illinois, United States

MAPS Applied Research Center, Inc.

Maple Grove, Minnesota, United States

Ainsworth Institute of Pain Management

New York, New York, United States

Center for Clinical Research

Winston-Salem, North Carolina, United States

Drexel University

Philadelphia, Pennsylvania, United States

Piedmont Comprehensive Pain Management

Greenville, South Carolina, United States

Virginia iSpine Physicians

Richmond, Virginia, United States

Advanced Pain Management

Greenfield, Wisconsin, United States

Countries

United States

References

Davis T, Loudermilk E, DePalma M, Hunter C, Lindley DA, Patel N, Choi D, Soloman M, Gupta A, Desai M, Cook E, Kapural L. Twelve-month analgesia and rescue, by cooled radiofrequency ablation treatment of osteoarthritic knee pain: results from a prospective, multicenter, randomized, cross-over trial. Reg Anesth Pain Med. 2019 Feb 16:rapm-2018-100051. doi: 10.1136/rapm-2018-100051. Online ahead of print.

Reference Type: DERIVED

PMID: 30772821 (View on PubMed)

Davis T, Loudermilk E, DePalma M, Hunter C, Lindley D, Patel N, Choi D, Soloman M, Gupta A, Desai M, Buvanendran A, Kapural L. Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. Reg Anesth Pain Med. 2018 Jan;43(1):84-91. doi: 10.1097/AAP.0000000000000690.

Reference Type: DERIVED

PMID: 29095245 (View on PubMed)

Other Identifiers

105-14-0001

Identifier Type: -

Identifier Source: org_study_id